Next Article in Journal
A Deep Learning Framework with Explainability for the Prediction of Lateral Locoregional Recurrences in Rectal Cancer Patients with Suspicious Lateral Lymph Nodes
Next Article in Special Issue
Diagnosing Cystic Fibrosis in the 21st Century—A Complex and Challenging Task
Previous Article in Journal
Retinal and Choroidal Changes Following Implantable Collamer Lens V4c Implantation in High Myopia Patients—A 1-Year Follow-Up Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 19
10.3390/diagnostics13193098
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans

by
Cathalijn Leenaars
1,*,
Christine Häger
1,
Frans Stafleu
2,
Hendrik Nieraad
1 and
André Bleich
1
1
Institute for Laboratory Animal Science, Hannover Medical School, 30625 Hannover, Germany
2
Department of Animals in Science and Society—Human-Animal Relationship, Utrecht University, 3584 CM Utrecht, The Netherlands
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(19), 3098; https://doi.org/10.3390/diagnostics13193098
Submission received: 29 June 2023 / Revised: 26 August 2023 / Accepted: 25 September 2023 / Published: 29 September 2023
(This article belongs to the Special Issue Advances in Diagnosis and Management of Cystic Fibrosis)
Browse Figures
Versions Notes

Abstract

:
To address unmet treatment needs in cystic fibrosis (CF), preclinical and clinical studies are warranted. Because it directly reflects the function of the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), the nasal potential difference test (nPD) can not only be used as a reliable diagnostic test for CF but also to assess efficacy of experimental treatments. We performed a full comprehensive systematic review of the effect of CF treatments on the nPD compared to control conditions tested in separate groups of animal and human subjects. Our review followed a preregistered protocol. We included 34 references: 20 describing mouse studies, 12 describing human studies, and 2 describing both. We provide a comprehensive list of these studies, which assessed the effects of antibiotics, bone marrow transplant, CFTR protein, CFTR RNA, directly and indirectly CFTR-targeting drugs, non-viral and viral gene transfer, and other treatments. Our results support the nPD representing a reliable method for testing treatment effects in both animal models and human patients, as well as for diagnosing CF. However, we also observed the need for improved reporting to ensure reproducibility of the experiments and quantitative comparability of the results within and between species (e.g., with meta-analyses). Currently, data gaps warrant further primary studies.

1. Introduction

Cystic fibrosis (CF) is a debilitating disease, with an incidence ranging from 1:2800 to 1:10,000, depending on the geographical region [1]. Whereas the cause of CF is known (i.e., mutations in the CFTR gene resulting in functional defects in the CFTR channel) [2], and with a large degree of understanding of the pathophysiology, there still are substantial unmet treatment needs [3,4,5]. To address these needs, new preclinical and clinical studies are still warranted.
Similarities with CF phenotype can be observed in CF animal models, for example, in electrophysiological parameters [6,7,8]. One of these parameters is the nasal potential difference (nPD), which improves when the CFTR channel function is corrected [9]. By specific changes in the protocol, the reliability of the nPD as a diagnostic test has increased [10,11]. The nPD can be measured in multiple species, e.g., mice [8], rats [6], and pigs [12], and is also used as an outcome measure in clinical trials for investigational CF treatments [9].
Preceding work from our group has shown that the predictive value of preclinical animal studies for human treatments ranges from 0% to 100% [13]. A later study found relevant differences in average predictive values between medical fields [14]. Therefore, we were interested in the predictive value of animal nPD values for human cystic fibrosis treatments. We aimed to answer this question by analyzing already published data in a systematic literature review (SR) while providing a comprehensive overview of CF treatments for which the effect on the nPD has been measured.
Based on the Cochrane handbook, we previously defined an SR as a “review comprising a full search resulting in a complete literature overview, inclusion of papers following strict criteria, tabulation of extracted data, risk of bias assessment of included studies, and meaningful (qualitative or quantitative) synthesis of the data” [15]. Our SR was designed to answer multiple review questions; in this manuscript, we focused on the data relating to potential CF treatment effects. In an elsewhere-submitted manuscript, we described the data relating to comparisons between cystic fibrosis and healthy controls [16].
Of note, methods for SRs of animal studies vary from those used for SRs of human studies (see [17] for an example of an elegant systematized review of human studies on the nPD in hypoxia-induced lung injury), mostly because the goals and experimental designs of animal studies are more variable. Whereas the development of methods for SRs of animal studies started later than that of human SR methods, several groups have proven the value of preclinical SRs in improving scientific practice [18,19,20,21,22,23], thereby decreasing the numbers of animals needed in pharmaceutical development. Because of the differences in review methods between fields, we provide an extensive description of our methods, with explanations for some of the decisions we made.

2. Materials and Methods

Our review was preregistered on PROSPERO (CRD42021236047) on 5 March 2021 [24]. Comprehensive searches in PubMed (comprising Medline) and Embase, unrestricted for publication date or language, were performed on 23 March 2021. A partial update was performed on 26 May 2023 and is described in the discussion. This review was reported in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.
The full search strings are shown in Table 1 and follow the PICO format. The population (P) consisted of animals and/or humans; the intervention (I) could be any intervention and was not part of the search, the comparison (C) could be any between-subject comparison and was not part of the search, and the outcome (O) was the nPD. As is common for SRs of animal studies, we added a separate search component for the disease: CF. The two strings for population were combined with “OR”. The results were combined with the other two strings with “AND”.
As the topic of this SR is clearly medical, we restricted our searches to the two main medical databases. This has been shown to be a sensitive approach, and it is in line with common practice in the field of laboratory animal SRs [26,27]. For SRs of animal studies with less medical topics, we strongly suggest adding at least one more database, e.g., CABabstracts to retrieve veterinary studies, or PsychInfo for SRs in the field of neuroscience. We did not search Google Scholar because it is impossible to run reproducible searches with this search engine [28]. We explicitly excluded anything other than full peer-reviewed publications, as we were interested in experimental design affecting the nPD, and descriptions of experimental design in conference abstracts are minimal. Consequently, we did not search the grey literature.
Title-abstract screening and full-text screening were performed in a blinded manner by two independent reviewers (FS and CL) using Rayyan [29]. Screening followed the predefined criteria listed in Table 2, as per protocol [24]. Reference lists of relevant reviews and included studies were manually screened by the same reviewers for further eligible studies. Discrepancies were all resolved by discussions between the reviewers.

2.1. Data Extraction

Data were extracted by two independent reviewers per reference in multiple distinct phases. In the first phase (FS and HN, discrepancies: FS and CL), basic data on study design and included population were extracted in Covidence [30]. These basic data allowed us to categorize the included studies into the CF versus control comparisons that were summarized in our other publication and the treatment studies that are summarized in this manuscript. In the second phase (FS and CL), risk-of-bias data were extracted for all treatment studies, also in Covidence. In the third phase (FS and CL), only the type of treatment was extracted, straight into a Microsoft Excel spreadsheet, to efficiently create an overview of the available studies without extracting too many data that could not be analyzed. Based on this third phase, we could determine the meta-analyses to be performed per protocol. In the fourth phase, (FS and CH), details on the treatment and outcomes for this planned meta-analysis (MA) were extracted in SRDR+. In all phases, discrepancies were resolved by discussion between the reviewers.
During the last phase of data extraction, standard deviations (SDs) were converted to Standard Errors of the Mean (SEMs). When values were not provided in text or tables, one of the extractors (CH) used pixel counts with digital imaging software (GIMP2.10.30), as previously described [31]; the other (FS) used an analogue ruler. When repeated post-treatment nPDs were reported, we extracted the value closest to 24 h after treatment. These data were exported from SRDR+ to Excel.

2.2. Risk of Bias Assessments

Risk of bias (RoB) and study quality were assessed with various tools, as per protocol [24]. In this paper, we summarize the overall RoB for all included treatment papers, following the SYRCLE and Cochrane tools [32,33]. To prevent multiple publications of the same data sets, analyses of the reporting quality data will only be presented in a separate publication on RoB and the quality of reporting in different types of animal and human studies.

2.3. Analysis

Data were checked and cleaned in Excel. Cleaning comprised harmonizing spelling and capitalization. For data exported from SRDR+, cleaning additionally comprised selection of the consolidated values and merging the data into a single wide data frame. We planned to perform meta-analyses comparing treatment effects between animal models and human patients, as described in our protocol [24]. Unfortunately, the amount of data required for these analyses was not available in the current literature (as described in the results section). Thus, we restricted our analyses of the included treatment studies to narrative and quantitative summaries.
All analyses were performed in R [34] via RStudio [35], using the following packages: readxl [36], dplyr [37], ggplot2 [38], and crosstable [39].

3. Results

3.1. Study Flow and Sample

Our PubMed search retrieved 943 publications, while our Embase search retrieved 1083. After the removal of 484 duplicates, 1542 titles and abstracts were screened. After excluding 1144 records in this phase, we retrieved 395 PDFs for full-text screening. Overall, 277 were excluded for the reasons shown in our overall reference flow (Figure 1). Hand searches of the reference lists of included studies and relevant reviews resulted in an additional 34 included studies.
Of the 151 references included in our overall SR, 34 described a comparison between a CF-targeting treatment and a between-subject control condition. Of these, k = 17 also described a comparison between CF and control without treatment, and these were also included in our parallel publication [16]. Full lists of the publications in each phase are available on the Open Science platform (https://doi.org/10.17605/OSF.IO/ST9MF accessed on 24 August 2023).
The here-described 34 references comprised 20 studies of CF treatments in mice, 12 of CF treatments in humans, and two studies in both species. Mouse references were published from 1993 to 2019. Human references were published from 1995 to 2014, and the two references describing both animal and human studies were from 1994 and 1996.

3.2. Included Treatments

The 34 included references described between one and six treatments each, which could mostly be categorized into eight types of treatment: antibiotics, bone marrow transplant, CFTR protein, CFTR RNA, directly CFTR-targeting drugs, indirectly CFTR-targeting drugs, non-viral gene transfer (NVGT), and viral gene transfer (VGT). Treatments that did not fit into these categories were grouped as “Other”. The numbers of included studies on these treatment types are visualized by species in Figure 2. The treatments are listed by category in Table 3. Full lists of the publications are available on the Open Science platform (https://doi.org/10.17605/OSF.IO/ST9MF accessed on 24 August 2023).

3.3. Risk of Bias

The median number of RoB items scored “unclear” per study was nine for animal and five for human treatment references, and the number ranged from three to nine. As in our preceding CF versus control analysis, human references scored significantly fewer “unclears,” reflecting more complete reporting than animal studies (W = 237.5, p < 0.001). The median number of RoB items scored “high” per references was one for both animal and human references. The median number of RoB items scored “low” per references was zero for animal and two for human references. The scores of the included treatment studies per item are shown in Figure 3, where the human references are listed in grey for the risk of bias related to housing.

3.4. Studies on Non-Viral Gene Therapy

The threshold to perform an MA, as specified in our protocol, was ≥3 animal model and ≥3 human studies reporting the nPD after treatment with a specific intervention. Based on the results shown in Table 1, which shows four NVGT studies in mice and four in humans, we were hopeful that overall, there would be enough data for an MA of the NVGT treatments. Additional data were thus extracted for the k = 8 NVGT references shown in Table 4. Full lists of the publications are available on the Open Science platform (https://doi.org/10.17605/OSF.IO/ST9MF accessed on 24 August 2023).
Publication dates for these references ranged from 1993 to 2002. Most of them described two-arm study designs comparing a treatment to a control. One study included both a sham and an untreated control [40], while another study described two distinct doses for NVGT [41]. All included NVGT references were written in English. Only three of the included references specifically mentioned the country of ethics evaluation, with two in the UK and one in the US. None of the eight included NVGT references mentioned a preregistration of the protocol, and seven referenced their methods.
Of the four human NVGT references, two described the inclusion of both genders, and two included males only. Sex was not mentioned in the four mouse references. The number of subjects studied ranged from 11 to 24 per reference. The nPD was tested from one to 18 times in these subjects. For our analyses, we selected a single nPD time point per included reference—the one closest to 24 h after treatment. For the included NVGT references, this resulted in nPDs from 16 h to 2 weeks after treatment, with substantial variation also within references. The NVGT treatment mainly (k = 7) comprised various kinds of liposomes, while only one study administered DNA complexes [42]. Control subjects were either untreated or received placebo/sham treatments.
After the control treatment, the baseline nPD ranged from 6.1 mV to 23.9 mV for mouse studies, and baseline nPD was 48.9 mV in the single included human study reporting this value. After NVGT treatment, the baseline nPD ranged from 13.1 mV to 23.9 mV for mouse studies and from 36.2 mV to 46.3 mV for human studies. Low chloride nPD values are not presented here because they were partially reported as a change to baseline and partially as absolute values.
To perform an MA, one needs the number of subjects and a measure of the variance besides the outcome measure for each included study. Unfortunately, the reporting of these important details was regularly lacking, as shown in Figure 4.
As the missing values were spread out over different studies, few of the data sets were complete (Figure 5). As this meant that the protocol-specified threshold was not met, we did not perform an MA.

4. Discussion

In this SR, we summarized the nPD after any CF treatment that was compared to a separate control group. We categorized the treatments into antibiotics [43], bone marrow transplant [44], CFTR protein [45], CFTR RNA [46,47], directly CFTR-targeting drugs [48,49], indirectly CFTR-targeting drugs (k = 11, refer to Table 1), NVGT (k = 8), VGT (k = 7), and other [50] treatments. As the first formal SR of the effects of CF treatments on the nPD, combining animal and human data, this could have been the leading data synthesis comparing efficacy between CF treatments, and treatment effects between animals and humans. However, there were large gaps in reporting, and the observed risk of bias was unclear for most included studies. Consequently, the overall evidence base per treatment category was too small to be conclusive, both for treatment effects and for animal–human comparability, even though we included more studies than many preceding reviews of animal studies, which has been reported to range, e.g., from 8 to 290 [23].
Even though our methods may look unfamiliar to those familiar with SRs of randomized clinical trials, the main strength this SR is its thorough methodology. The protocol was posted on the PROSPERO register [24] to prevent the cherry-picking of results, hypothesizing after the results were known (HARKing), and other teams duplicating our efforts [15]. We performed comprehensive searches in the two main medical databases, and all references were screened by two independent reviewers to minimize the chance of missing relevant records. To prevent errors, the study design parameters, outcome data, and risk of bias data were also extracted by two independent reviewers. To summarize, we followed all viable measures to minimize bias introduced during the review process.
The main limitation is the low amount of included data. There are three potential explanations: (1) incomplete sampling due to review methods; (2) the date of our search; or (3) lacking evidence within the published literature. Concerning sampling, the main limitation was that we only included between-subject comparisons and cross-over designs. Because within-subject comparisons can introduce bias due to time-associated factors, these were excluded. Based on the abstracts we read during screening, we estimated that including these less stringent experimental designs could have increased the amount of included data up to 30%, still leaving significant knowledge gaps.
Our search date of 23 March 2021 could be seen as a limitation. However, SRs generally take a long time to complete, with a median of 66 weeks and extremes up to 186 from start to completion [51]. With longer review durations, full review updates are crucial if the newly available literature could alter the conclusions of a review; thus, we tested if an update would be informative. To scope the amount of newly available literature, we repeated our searches in PubMed on 26 May 2023, with the publication date filtered to retrieve only references published after our original search. This search resulted in 87 hits. Rapid screening of these 87 hits was performed by a single reviewer (CL) in a single phase (exclude based on title and abstract or immediately retrieve PDF and include/exclude based on full text), with labelling for the treatment category during screening. Based on the title-abstract only, 75 references were excluded. Based on the full texts, another five references were excluded (three did not describe primary studies and two had the wrong study design). The full text of one reference [52] could not be retrieved directly. From the six included references, five were only relevant for our CF-Control comparisons [53,54,55,56,57]. The remaining reference, which would be included in a formal update of this part of our SR, described the effect of treatment with the CFTR-corrector c407 in mice [58]. Searching Embase in addition to PubMed, combined with further adaptations of the methods, may have resulted in a few additional references. However, based on this informal update, we do not expect a full update to change the conclusions of our review, and it would delay publication of these findings further.
In the opinion of the authors, further SRs of the nPD for CF treatmens are pointless until more primary data, resulting in a more informative overall evidence base, become available. In the meantime, preclinical SR efforts could focus on other important aspects of CF, such as the relationship between body weigh/body composition and clinical outcomes. Whereas several clinical reviews have assessed this subject (e.g., [59,60]), the preclinical evidence has not yet been reviewed. For overall CF treatment effects assessing multiple outcomes, the preclinical evidence base is also possibly relevant. Moreover, more meaningful analyses were possible in comparing baseline nPD values between animal models and patients, as shown in our other manuscript [16].
As described in the introduction, we defined an SR as a “review comprising a full search resulting in a complete literature overview, inclusion of papers following strict criteria, tabulation of extracted data, risk of bias assessment of included studies, and meaningful (qualitative or quantitative) synthesis of the data.” This definition is more stringent than some others (e.g., [27]), but we strongly encourage the use of other terms (mainly “mapping review” and “scoping review”) for reviews partially using systematic methods [15]. We followed our definition and synthesized the available data as meaningfully as possible, in line with previous SRs [27,61].
Whereas the nPD remains a reliable test for diagnosing CF and for testing treatment effects in animal models and human patients, there is a huge need to improve the reporting of the results to ensure reproducibility of the experiments within and between species. Particularly because the technique of measuring the nPD is complicated, and because different laboratories use different protocols, it is crucial for primary studies to report the actual outcome data together with the associated variance, numbers of subjects, and all study design parameters. This SR shows that missing data from several of the included studies made the planned analyses impossible, limiting the value of our efforts.

Author Contributions

Conceptualization, C.L. and A.B.; methodology, C.L., F.S., C.H., H.N. and A.B.; validation, C.H.; formal analysis, C.L.; investigation, C.L., F.S., C.H. and H.N; resources, C.L. and A.B.; data curation, C.L.; writing—original draft preparation, C.L.; writing—review and editing, H.N., C.H., F.S. and A.B.; visualization, C.L.; supervision, C.L. and A.B.; project administration, C.L.; funding acquisition, C.L. and A.B. All authors have read and agreed to the published version of the manuscript.

Funding

This research and the APC were funded by the “Bundesministerium für Bildung und Forschung” (BMBF, the German Federal Ministry of Education and Research), grant number 01KC1904.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

All used search strings are publicly available within one of the references. All search results, screening results, and extracted data are available on OSF (https://doi.org/10.17605/OSF.IO/ST9MF).

Acknowledgments

The authors kindly acknowledge Antje Munder for providing advise on the review protocol as a CF expert.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Scotet, V.; Gutierrez, H.; Farrell, P.M. Newborn Screening for CF across the Globe-Where Is It Worthwhile? Int. J. Neonatal Screen. 2020, 6, 18. [Google Scholar] [CrossRef]
  2. Kerem, B.; Rommens, J.M.; Buchanan, J.A.; Markiewicz, D.; Cox, T.K.; Chakravarti, A.; Buchwald, M.; Tsui, L.C. Identification of the cystic fibrosis gene: Genetic analysis. Science 1989, 245, 1073–1080. [Google Scholar] [CrossRef] [PubMed]
  3. Dubin, E.; Lowers, J.; Dellon, E.P.; Hempstead, S.; Faro, A.; Tallarico, E.; Fitzpatrick, A.; Hunt, W.R.; Kavalieratos, D. Prevalence of unmet pain and symptom management needs in adults with cystic fibrosis. J. Cyst. Fibros. 2022. [Google Scholar] [CrossRef]
  4. Kramer-Golinkoff, E.; Camacho, A.; Kramer, L.; Taylor-Cousar, J.L. A survey: Understanding the health and perspectives of people with CF not benefiting from CFTR modulators. Pediatr. Pulmonol. 2022, 57, 1253–1261. [Google Scholar] [CrossRef] [PubMed]
  5. Stanford, G.E.; Dave, K.; Simmonds, N.J. Pulmonary Exacerbations in Adults With Cystic Fibrosis: A Grown-up Issue in a Changing Cystic Fibrosis Landscape. Chest 2021, 159, 93–102. [Google Scholar] [CrossRef] [PubMed]
  6. Dreano, E.; Bacchetta, M.; Simonin, J.; Galmiche, L.; Usal, C.; Slimani, L.; Sadoine, J.; Tesson, L.; Anegon, I.; Concordet, J.; et al. Characterization of two rat models of cystic fibrosis: F508del and KO CFTR generated by CRISPR-Cas9. Pediatr. Pulmonol. 2019, 54, 318–319. [Google Scholar] [CrossRef]
  7. Knowles, M.R.; Gatzy, J.T.; Boucher, R.C. Increased bioelectric potential differences across respiratory epithelia in cystic fibrosis. N. Engl. Med. 1981, 305, 1489–1495. [Google Scholar] [CrossRef] [PubMed]
  8. Saussereau, E.L.; Roussel, D.; Diallo, S.; Debarbieux, L.; Edelman, A.; Sermet-Gaudelus, I. Characterization of nasal potential difference in CFTR knockout and F508del-CFTR mice. PLoS ONE 2013, 8, e57317. [Google Scholar] [CrossRef]
  9. Standaert, T.A.; Boitano, L.; Emerson, J.; Milgram, L.J.; Konstan, M.W.; Hunter, J.; Berclaz, P.Y.; Brass, L.; Zeitlin, P.L.; Hammond, K.; et al. Standardized procedure for measurement of nasal potential difference: An outcome measure in multicenter cystic fibrosis clinical trials. Pediatr. Pulmonol. 2004, 37, 385–392. [Google Scholar] [CrossRef]
  10. Middleton, P.G.; Geddes, D.M.; Alton, E.W. Protocols for in vivo measurement of the ion transport defects in cystic fibrosis nasal epithelium. Eur. Respir. J. 1994, 7, 2050–2056. [Google Scholar] [CrossRef]
  11. Naehrlich, L.; Ballmann, M.; Davies, J.; Derichs, N.; Gonska, T.; Hjelte, L.; van Konigsbruggen-Rietschel, S.; Leal, T.; Melotti, P.; Middleton, P.; et al. Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. J. Cyst. Fibros. 2014, 13, 24–28. [Google Scholar] [CrossRef] [PubMed]
  12. Rogers, C.S.; Stoltz, D.A.; Meyerholz, D.K.; Ostedgaard, L.S.; Rokhlina, T.; Taft, P.J.; Rogan, M.P.; Pezzulo, A.A.; Karp, P.H.; Itani, O.A.; et al. Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science 2008, 321, 1837–1841. [Google Scholar] [CrossRef] [PubMed]
  13. Leenaars, C.H.C.; Kouwenaar, C.; Stafleu, F.R.; Bleich, A.; Ritskes-Hoitinga, M.; De Vries, R.B.M.; Meijboom, F.L.B. Animal to human translation: A systematic scoping review of reported concordance rates. J. Transl. Med. 2019, 17, 223. [Google Scholar] [CrossRef] [PubMed]
  14. Van de Wall, G.; Van Hattem, A.; Timmermans, J.; Ritskes-Hoitinga, M.; Bleich, A.; Leenaars, C. Comparing Translational Success Rates across Medical Research Fields: A combined analysis of literature and clinical trial data. ALTEX 2023. [Google Scholar] [CrossRef]
  15. Leenaars, C.; Tsaioun, K.; Stafleu, F.; Rooney, K.; Meijboom, F.; Ritskes-Hoitinga, M.; Bleich, A. Reviewing the animal literature: How to describe and choose between different types of literature reviews. Lab. Anim. 2021, 55, 129–141. [Google Scholar] [CrossRef] [PubMed]
  16. Leenaars, C.; Stafleu, F.; Häger, C.; Nieraad, H.; Bleich, A. The nasal potential difference test: A systematic review of animal and human data comparing cystic fibrosis to control. 2023; Submitted manuscript. [Google Scholar]
  17. Su, Z.; Zhu, L.; Wu, J.; Zhao, R.; Ji, H.L. Systematic review and meta-analysis of nasal potential difference in hypoxia-induced lung injury. Sci. Rep. 2016, 6, 30780. [Google Scholar] [CrossRef]
  18. de Vries, R.B.; Wever, K.E.; Avey, M.T.; Stephens, M.L.; Sena, E.S.; Leenaars, M. The usefulness of systematic reviews of animal experiments for the design of preclinical and clinical studies. ILAR J. 2014, 55, 427–437. [Google Scholar] [CrossRef]
  19. Hooijmans, C.R.; IntHout, J.; Ritskes-Hoitinga, M.; Rovers, M.M. Meta-analyses of animal studies: An introduction of a valuable instrument to further improve healthcare. ILAR J. 2014, 55, 418–426. [Google Scholar] [CrossRef]
  20. Hooijmans, C.R.; Ritskes-Hoitinga, M. Progress in using systematic reviews of animal studies to improve translational research. PLoS Med. 2013, 10, e1001482. [Google Scholar] [CrossRef]
  21. Howells, D.W.; Sena, E.S.; O’Collins, V.; Macleod, M.R. Improving the efficiency of the development of drugs for stroke. Int. J. Stroke 2012, 7, 371–377. [Google Scholar] [CrossRef] [PubMed]
  22. Sena, E.S.; Currie, G.L.; McCann, S.K.; Macleod, M.R.; Howells, D.W. Systematic reviews and meta-analysis of preclinical studies: Why perform them and how to appraise them critically. J. Cereb. Blood Flow. Metab. 2014, 34, 737–742. [Google Scholar] [CrossRef] [PubMed]
  23. van der Worp, H.B.; Howells, D.W.; Sena, E.S.; Porritt, M.J.; Rewell, S.; O’Collins, V.; Macleod, M.R. Can animal models of disease reliably inform human studies? PLoS Med. 2010, 7, e1000245. [Google Scholar] [CrossRef] [PubMed]
  24. Leenaars, C.; Stafleu, F.; Bleich, A. The Nasal Potential Difference Test for Diagnosing Cystic Fibrosis and Assessing Disease Severity: A Systematic Review. Preregisterred Protocol on PROSPERO (York, UK), Registration Number CRD42021236047. 2021. Available online: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021236047 (accessed on 26 August 2023).
  25. van der Mierden, S.; Hooijmans, C.R.; Tillema, A.H.; Rehn, S.; Bleich, A.; Leenaars, C.H. Laboratory animals search filter for different literature databases: PubMed, Embase, Web of Science and PsycINFO. Lab. Anim. 2022, 56, 279–286. [Google Scholar] [CrossRef] [PubMed]
  26. Van Luijk, J.A.K.R. The Next Steps Towards Responsible Animal-Based Research; RadboudUMC: Nijmegen, The Netherlands, 2017. [Google Scholar]
  27. Langendam, M.W.; Magnuson, K.; Williams, A.R.; Walker, V.R.; Howdeshell, K.L.; Rooney, A.A.; Hooijmans, C.R. Developing a database of systematic reviews of animal studies. Regul. Toxicol. Pharmacol. 2021, 123, 104940. [Google Scholar] [CrossRef] [PubMed]
  28. Haddaway, N.R.; Collins, A.M.; Coughlin, D.; Kirk, S. The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching. PLoS ONE 2015, 10, e0138237. [Google Scholar] [CrossRef]
  29. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. Syst. Rev. 2016, 5, 210. [Google Scholar] [CrossRef]
  30. Covidence Systematic Review Software. Available online: www.covidence.org (accessed on 18 April 2023).
  31. Van der Mierden, S.; Spineli, L.M.; Talbot, S.R.; Yiannakou, C.; Zentrich, E.; Weegh, N.; Struve, B.; Zur Brugge, T.F.; Bleich, A.; Leenaars, C.H.C. Extracting data from graphs: A case-study on animal research with implications for meta-analyses. Res. Synth. Methods 2021, 12, 701–710. [Google Scholar] [CrossRef]
  32. Higgins, J.P.T.; Savović, J.; Page, M.J.; Elbers, R.G.; Sterne, J.A.C. Chapter 8: Assessing risk of bias in a randomized trial. In Cochrane Handbook for Systematic Reviews of Interventions; Cochrane: London, UK, 2022. [Google Scholar]
  33. Hooijmans, C.R.; Rovers, M.M.; de Vries, R.B.; Leenaars, M.; Ritskes-Hoitinga, M.; Langendam, M.W. SYRCLE’s risk of bias tool for animal studies. BMC Med. Res. Methodol. 2014, 14, 43. [Google Scholar] [CrossRef]
  34. R_Core_Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2021. [Google Scholar]
  35. RStudio Team. RStudio: Integrated Development for R, PBC, Boston, MA. Available online: http://www.rstudio.com/ (accessed on 24 September 2023).
  36. Wickham, H.; Bryan, J. readxl: Read Excel Files, R Package Version 1.4.2; TX & CA, USA. 2019. Available online: https://CRAN.R-project.org/package=readxl (accessed on 24 September 2023).
  37. Wickham, H.; François, R.; Henry, L.; Müller, K. dplyr: A Grammar of Data Manipulation, R Package Version 1.1.2. 2023. Available online: https://CRAN.R-project.org/package=dplyr (accessed on 24 September 2023).
  38. Wickham, H. ggplot2: Elegant Graphics for Data Analysis; Springer: New York, NY, USA, 2016. [Google Scholar]
  39. Chaltiel, D. crosstable: Crosstables for Descriptive Analyses, R Package Version 0.6.2; Villejuif, FR. 2023. Available online: https://CRAN.R-project.org/package=crosstable (accessed on 24 September 2023).
  40. Jiang, C.; O’Connor, S.P.; Fang, S.L.; Wang, K.X.; Marshall, J.; Williams, J.L.; Wilburn, B.; Echelard, Y.; Cheng, S.H. Efficiency of cationic lipid-mediated transfection of polarized and differentiated airway epithelial cells in vitro and in vivo. Hum. Gene Ther. 1998, 9, 1531–1542. [Google Scholar] [CrossRef]
  41. Gill, D.R.; Southern, K.W.; Mofford, K.A.; Seddon, T.; Huang, L.; Sorgi, F.; Thomson, A.; MacVinish, L.J.; Ratcliff, R.; Bilton, D.; et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 1997, 4, 199–209. [Google Scholar] [CrossRef]
  42. Ziady, A.G.; Kelley, T.J.; Milliken, E.; Ferkol, T.; Davis, P.B. Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptor. Mol. Ther. 2002, 5, 413–419. [Google Scholar] [CrossRef] [PubMed]
  43. Barker, P.M.; Gillie, D.J.; Schechter, M.S.; Rubin, B.K. Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epithelium. Am. J. Respir. Crit. Care Med. 2005, 171, 868–871. [Google Scholar] [CrossRef] [PubMed]
  44. Bruscia, E.M.; Price, J.E.; Cheng, E.C.; Weiner, S.; Caputo, C.; Ferreira, E.C.; Egan, M.E.; Krause, D.S. Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantation. Proc. Natl. Acad. Sci. USA 2006, 103, 2965–2970. [Google Scholar] [CrossRef]
  45. Ramjeesingh, M.; Huan, L.J.; Wilschanski, M.; Durie, P.; Li, C.; Gyomorey, K.; Wang, Y.; Kent, G.; Tanswell, K.A.; Cutz, E.; et al. Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF mice. Hum. Gene Ther. 1998, 9, 521–528. [Google Scholar] [CrossRef]
  46. Beumer, W.; Swildens, J.; Leal, T.; Noel, S.; Anthonijsz, H.; van der Horst, G.; Kuiperij-Boersma, H.; Potman, M.; van Putten, C.; Biasutto, P.; et al. Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosis. PLoS ONE 2019, 14, e0219182. [Google Scholar] [CrossRef] [PubMed]
  47. Robinson, E.; MacDonald, K.D.; Slaughter, K.; McKinney, M.; Patel, S.; Sun, C.; Sahay, G. Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. Mol. Ther. 2018, 26, 2034–2046. [Google Scholar] [CrossRef] [PubMed]
  48. Accurso, F.J.; Van Goor, F.; Zha, J.; Stone, A.J.; Dong, Q.; Ordonez, C.L.; Rowe, S.M.; Clancy, J.P.; Konstan, M.W.; Hoch, H.E.; et al. Sweat chloride as a biomarker of CFTR activity: Proof of concept and ivacaftor clinical trial data. J. Cyst. Fibros. 2014, 13, 139–147. [Google Scholar] [CrossRef] [PubMed]
  49. Rowe, S.M.; Liu, B.; Hill, A.; Hathorne, H.; Cohen, M.; Beamer, J.R.; Accurso, F.J.; Dong, Q.; Ordoñez, C.L.; Stone, A.J.; et al. Optimizing nasal potential difference analysis for CFTR modulator development: Assessment of ivacaftor in CF subjects with the G551D-CFTR mutation. PLoS ONE 2013, 8, e66955. [Google Scholar] [CrossRef]
  50. Lazrak, A.; Jurkuvenaite, A.; Ness, E.C.; Zhang, S.; Woodworth, B.A.; Muhlebach, M.S.; Stober, V.P.; Lim, Y.P.; Garantziotis, S.; Matalon, S. Inter-α-inhibitor blocks epithelial sodium channel activation and decreases nasal potential differences in ΔF508 mice. Am. J. Respir. Cell Mol. Biol. 2014, 50, 953–962. [Google Scholar] [CrossRef]
  51. Borah, R.; Brown, A.W.; Capers, P.L.; Kaiser, K.A. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open 2017, 7, e012545. [Google Scholar] [CrossRef] [PubMed]
  52. Drummond, D.; Dana, J.; Berteloot, L.; Schneider-Futschik, E.K.; Chedevergne, F.; Bailly-Botuha, C.; Nguyen-Khoa, T.; Cornet, M.; Le Bourgeois, M.; Debray, D.; et al. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. J. Cyst. Fibros. 2022, 21, 212–219. [Google Scholar] [CrossRef]
  53. Piotrowski-Daspit, A.S.; Barone, C.; Lin, C.Y.; Deng, Y.; Wu, D.; Binns, T.C.; Xu, E.; Ricciardi, A.S.; Putman, R.; Garrison, A.; et al. In vivo correction of cystic fibrosis mediated by PNA nanoparticles. Sci. Adv. 2022, 8, eabo0522. [Google Scholar] [CrossRef]
  54. Noel, S.; Servel, N.; Hatton, A.; Golec, A.; Rodrat, M.; Ng, D.R.S.; Li, H.; Pranke, I.; Hinzpeter, A.; Edelman, A.; et al. Correlating genotype with phenotype using CFTR-mediated whole-cell Cl(-) currents in human nasal epithelial cells. J. Physiol. 2022, 600, 1515–1531. [Google Scholar] [CrossRef]
  55. Reyne, N.; Cmielewski, P.; McCarron, A.; Delhove, J.; Parsons, D.; Donnelley, M. Single-Dose Lentiviral Mediated Gene Therapy Recovers CFTR Function in Cystic Fibrosis Knockout Rats. Front. Pharmacol. 2021, 12, 682299. [Google Scholar] [CrossRef] [PubMed]
  56. Sermet-Gaudelus, I.; Nguyen-Khoa, T.; Hatton, A.; Hayes, K.; Pranke, I. Sweat Chloride Testing and Nasal Potential Difference (NPD) Are Primary Outcome Parameters in Treatment with Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators. J. Pers. Med. 2021, 11, 729. [Google Scholar] [CrossRef] [PubMed]
  57. Cmielewski, P.; Delhove, J.; Donnelley, M.; Parsons, D. Assessment of Lentiviral Vector Mediated CFTR Correction in Mice Using an Improved Rapid in vivo Nasal Potential Difference Measurement Protocol. Front. Pharmacol. 2021, 12, 714452. [Google Scholar] [CrossRef] [PubMed]
  58. da Cunha, M.F.; Pranke, I.; Sassi, A.; Schreiweis, C.; Moriceau, S.; Vidovic, D.; Hatton, A.; Carlon, M.S.; Creste, G.; Berhal, F.; et al. Systemic bis-phosphinic acid derivative restores chloride transport in Cystic Fibrosis mice. Sci. Rep. 2022, 12, 6132. [Google Scholar] [CrossRef] [PubMed]
  59. Calella, P.; Valerio, G.; Brodlie, M.; Donini, L.M.; Siervo, M. Cystic fibrosis, body composition, and health outcomes: A systematic review. Nutrition 2018, 55–56, 131–139. [Google Scholar] [CrossRef]
  60. Mielus, M.; Sands, D.; Woynarowski, M. Improving nutrition in cystic fibrosis: A systematic literature review. Nutrition 2022, 102, 111725. [Google Scholar] [CrossRef]
  61. Aquarius, R.; Elbertsen, D.; de Vries, J.; Boogaarts, H.D.; Wever, K.E. A systematic review of the Woven EndoBridge device-do findings in pre-clinical animal models compare to clinical results? Acta Neurochir. 2023, 165, 1869–1879. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 13 03098 g001
Figure 1. Reference flow.
Figure 1. Reference flow.
Diagnostics 13 03098 g001
Diagnostics 13 03098 g002
Figure 2. Categorization of the included treatments. (a) Treatments in animal studies; (b) treatments in human studies. The white wedge reflects the number of human studies that are “missing” compared to the number of animal studies.
Figure 2. Categorization of the included treatments. (a) Treatments in animal studies; (b) treatments in human studies. The white wedge reflects the number of human studies that are “missing” compared to the number of animal studies.
Diagnostics 13 03098 g002
Diagnostics 13 03098 g003
Figure 3. Summary of the risk of bias.
Figure 3. Summary of the risk of bias.
Diagnostics 13 03098 g003
Diagnostics 13 03098 g004
Figure 4. Heatmap of the missing nPD data in the included NVGT studies for the k = 8 NVGT treatment references. Green: no missing information. Yellow to dark red: increasing amounts of missing information.
Figure 4. Heatmap of the missing nPD data in the included NVGT studies for the k = 8 NVGT treatment references. Green: no missing information. Yellow to dark red: increasing amounts of missing information.
Diagnostics 13 03098 g004
Diagnostics 13 03098 g005
Figure 5. Heatmap of complete nPD data sets for NVGT treatments. Yellow and red reflect insufficient data; according to our protocol, we needed at least three of each population to perform a meta-analysis.
Figure 5. Heatmap of complete nPD data sets for NVGT treatments. Yellow and red reflect insufficient data; according to our protocol, we needed at least three of each population to perform a meta-analysis.
Diagnostics 13 03098 g005
Table 1. Full search strings.
Table 1. Full search strings.
PubMed
nPDMembrane potentials [MeSH:NoExp] OR ((Nasa*[tiab] OR naso*[tiab] OR membran*[tiab] OR transmembran*[tiab]) AND (Potential[tiab] OR potentials[tiab] OR voltage[tiab] OR voltages[tiab] OR current[tiab] OR currents[tiab]) AND (Difference[tiab] OR differences[tiab] or change[tiab] OR changes[tiab] OR alteration[tiab] OR alterations[tiab] OR variance[tiab]))
CFCystic fibrosis [MeSH] OR Mice, Inbred CFTR [MeSH] OR Cystic Fibrosis Transmembrane Conductance Regulator [MeSH] OR (cystic[tiab] AND (fibrosis[tiab] OR fibroses[tiab] OR fibrotic[tiab])) OR Mucoviscidos* [tiab] OR Mucoviscoid* [tiab] OR Mukoviszid* [tiab] OR CFTR [tiab] OR Fibrocystic Dis-ease [tiab] OR Fibrocystic Diseases [tiab] OR Mckusick [tiab] OR CFRD [tiab] OR “pancreas cystic disease” [tiab] OR muco-patient* [tiab] OR muko-patient* [tiab] OR (CF [tiab] AND (lung [tiab] OR lungs [tiab] OR pulmonary [tiab] OR ABPA [tiab] OR mucus [tiab] OR liver [tiab] OR livers [tiab] OR steatosis [tiab] OR cirrhosis [tiab] OR cirrhotic [tiab] OR meconium ileus[tiab] OR gastrointestinal [tiab] OR intestine [tiab] OR intestines [tiab] OR intestinal [tiab] OR duodenum [tiab] OR jejunum [tiab] OR colon [tiab] OR caecum [tiab] OR DIOS [tiab] OR ((sweat [tiab] OR eccrine [tiab] OR apocrine [tiab] OR salivary [tiab] OR parotid [tiab] OR sublingual [tiab] OR submandibular [tiab] OR sub-lingual [tiab] OR sub-mandibular [tiab] OR von Ebner [tiab]) AND (gland [tiab] OR glands [tiab])) OR ((Pa-ranasal [tiab] OR Para-nasal [tiab] OR frontal [tiab] OR ethmoidal [tiab] OR maxillary [tiab] OR sphenoidal [tiab]) AND (sinus [tiab] OR sinuses [tiab])) OR pancreas [tiab] OR pancreatic [tiab]))
Humanclinical study [pt] OR clinical trial [tiab] OR intervention study [tiab] OR “clinical studies as topic”[MeSH] OR first in man [tiab] OR proof of concept [tiab] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab] OR multicenter study[pt] OR “Multicenter Studies as Topic” [Mesh]
AnimalPubMed animal filter [25]
Embase
nPDexp potential difference/OR (exp nose/AND exp electrical parameters/) OR ((Nasa* OR naso* OR membran* or transmembran*) AND (Potential OR potentials OR voltage OR voltages OR current OR currents) AND (Difference OR differences or change OR changes OR alteration OR alterations OR variance)).ti,ab,kw.
CFCystic fibrosis/OR cystic fibrosis transmembrane conductance regulator/OR (cystic adj2 fibros*).ti,ab,kw. OR fibrocystic diseas*.ti,ab,kw. OR (mucovisc* or Mukoviszidose).ti,ab,kw. OR CFRD.ti,ab,kw. OR muco-patient*.ti,ab,kw. OR muko-patient*.ti,ab,kw. OR pancreas cystic disease.ti,ab,kw. OR pancreas fibrocystic disease.ti,ab,kw. OR pancreas fibrosis.ti,ab,kw. OR pancreatic cystic disease.ti,ab,kw. OR pancreatic fibrosis.ti,ab,kw. OR (CF adj30 (lung OR liver OR stomach OR intestines OR pulmonary OR meconeum ileus OR gastrointestinal OR intestine OR intestines OR intestinal OR pancreas OR pancreatic OR ((sweat OR eccrine OR apocrine OR salivary OR parotid OR sublingual OR submandibular OR von Ebner) adj2 (gland OR glands)) OR ((Paranasal OR frontal OR ethmoidal OR maxillary OR sphenoidal) adj2 (sinus OR sinusses)))).ti,ab,kw.
Humanexp clinical trial/OR clinical study/OR human subject.ti,ab,kw. OR clinical drug trial.ti,ab,kw. OR major clinical trial.ti,ab,kw. OR trial, clinical.ti,ab,kw. OR clinical study.ti,ab,kw. OR phase 1 clinical trial.ti,ab,kw. OR phase 2 clinical trial.ti,ab,kw. OR phase 3 clinical trial.ti,ab,kw. OR clinical trial, controlled.ti,ab,kw. OR clinical trial, phase 1.ti,ab,kw. OR clinical trial, phase 2.ti,ab,kw. OR clinical trial, phase 3.ti,ab,kw. OR clinical trials.ti,ab,kw. OR clinical trial, phase I.ti,ab,kw. OR clinical trial, phase II.ti,ab,kw. OR clinical trial, phase III.ti,ab,kw. OR intervention study.ti,ab,kw.
AnimalEmbase animal filter [25]
Table 2. Exclusion criteria and the phases in which they were used.
Table 2. Exclusion criteria and the phases in which they were used.
Screening Phase
Exclusion Criterium 1Title-AbstractFull Text
Study not about CFXX
Study not in vivo 2XX
No nPD measuredXX
No untreated control group (either with or without CF) 3 present X
No full peer-reviewed publication 4 X
1 There were no restrictions for publication date or language. 2 Ex vivo, in vitro and in silico models were excluded. 3 For the full review, we included both studies that compared CF with healthy controls at baseline and studies that compared treated with untreated CF. In this publication we only present the second category, as selected in the first phase of data extraction (see below). 4 Conference proceedings and short communications lacking a detailed description of the methods were excluded because we planned analyses of the experimental set-ups.
Table 3. Treatments for which nPD data were published.
Table 3. Treatments for which nPD data were published.
Study ID 1TitlePopulationTreatment
Antibiotics
Barker_2005Effect of macrolides on in vivo ion transport across cystic fibrosis nasal epitheliumHumansClarithromycin; Azithromycin
Bone Marrow Transplant
Bruscia_2006Assessment of cystic fibrosis transmembrane conductance regulator (CFTR) activity in CFTR-null mice after bone marrow transplantationAnimals
Direct CFTR targeting drugs
Accurso_2014Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial dataHumansIvacaftor
Rowe_2013Optimizing nasal potential difference analysis for CFTR modulator development: assessment of ivacaftor in CF subjects with the G551D-CFTR mutationHumansIvacaftor
Indirect CFTR-affecting drugs
Cartiera_2010Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcuminAnimalsCurcumin
Clancy_2012Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutationHumansVX-809
Egan_2002Calcium-pump inhibitors induce functional surface expression of DELTAF508-CFTR protein in cystic fibrosis epithelial cellsAnimalsThapsigargin
Egan_2004Curcumin, a major constituent of turmeric, corrects cystic fibrosis defectsAnimalsCurcumin
Kerem_2014Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trialHumansAtaluren
Lubamba_2008Preclinical evidence that sildenafil and vardenafil activate chloride transport in cystic fibrosisAnimalsSildenafil and Vardenafil
Lubamba_2009Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis miceAnimalsMiglustat
Lubamba_2011Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis miceAnimalsType-5 phosphodiesterase inhibitors
McCarty_2002A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosisHumansCPX
Rubenstein_1998A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR functionHumansBuphenyl (sodium-4-phenylbutyrate)
Zeitlin_2002Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrateHumansBuphenyl (sodium-4-phenylbutyrate)
Non-Viral Gene Transfer (NVGT)
Alton_1993Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant miceAnimalsCFTR cDNA-liposome complexes (DC-Chol/DOPE)
Alton_1999Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trialHumansCationic lipid-mediated gene transfer (GL-67/DOPE/DMPE-PEG500)
Caplen_1995Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosisHumansComplementary DNA in liposomes
Gill_1997A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosisHumansLiposome-mediated gene transfer
Hyde_2000Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosisHumansDNA/liposomes
Jiang_1998Efficiency of cationic lipid-mediated transfection of polarized and differentiated airway epithelial cells in vitro and in vivoAnimalsCL-67 mediated gene transduction (cationic lipid)
McLachlan_1996Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAPBothGene therapy using pCMV-CFTR-DOTAP
Ziady_2002Functional evidence of CFTR gene transfer in nasal epithelium of cystic fibrosis mice in vivo following luminal application of DNA complexes targeted to the serpin-enzyme complex receptorAnimalsCFTR gene transfer with serpin-targeted molecular conjugates
Other
Lazrak_2014Inter-α-inhibitor blocks epithelial sodium channel activation and decreases nasal potential differences in ΔF508 miceAnimalsInter-alpha inhibitor
Protein
Ramjeesingh_1998Assessment of the efficacy of in vivo CFTR protein replacement therapy in CF miceAnimalsPurified CFTR protein via phospholipid liposomes
RNA
Beumer_2019Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosisAnimalsEluforsen
Robinson_2018Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic FibrosisAnimalslipid nanoparticle-delivered chemically modified mRNA
Viral Gene Transfer (VGT)
Cmielewski_2014Long-term therapeutic and reporter gene expression in lentiviral vector treated cystic fibrosis miceAnimalsCFTR gene in lentiviral vector
Grubb_1994Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humansBothGene transfer by adenovirus
Jiang_1997Increased contact time improves adenovirus-mediated CFTR gene transfer to nasal epithelium of CF miceAnimalsAdenovirus-mediated gene transfer
Limberis_2002Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transferAnimalsLentivirus-Mediated Gene Transfer
Ostedgaard_2002CFTR with a partially deleted R domain corrects the cystic fibrosis chloride transport defect in human airway epithelia in vitro and in mouse nasal mucosa in vivoAnimalsAdenoviral vectors
Parsons_1998Enhanced in vivo airway gene transfer via transient modification of host barrier properties with a surface-active agentAnimalsAdenoviral gene transfer
Vidovic_2016rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis MiceAnimalsrAAV vector containing truncated CFTR
1 Full citations are available in the data files on the open science platform.
Table 4. NVGT studies.
Table 4. NVGT studies.
Study_ID 1Ethics ReviewSpeciesSex/GenderN StudiedNumber of RepetitionsTime after Treatment
Alton_1993 Micenr16116–68 h
Alton_1999UKHumansMales1681 day
Caplen_1995 HumansMales1561 day
Gill_1997A HumansBoth1211mean value of day 10, 12 and 14
Gill_1997B HumansBoth1211mean value of day 10, 12 and 14
Hyde_2000UKHumansBoth1218Days 2–7
Jiang_1998 Micenr151nr
1 Full citations are available in the data files on the open science platform.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Leenaars, C.; Häger, C.; Stafleu, F.; Nieraad, H.; Bleich, A. A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans. Diagnostics 2023, 13, 3098. https://doi.org/10.3390/diagnostics13193098

AMA Style

Leenaars C, Häger C, Stafleu F, Nieraad H, Bleich A. A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans. Diagnostics. 2023; 13(19):3098. https://doi.org/10.3390/diagnostics13193098

Chicago/Turabian Style

Leenaars, Cathalijn, Christine Häger, Frans Stafleu, Hendrik Nieraad, and André Bleich. 2023. "A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans" Diagnostics 13, no. 19: 3098. https://doi.org/10.3390/diagnostics13193098

APA Style

Leenaars, C., Häger, C., Stafleu, F., Nieraad, H., & Bleich, A. (2023). A Systematic Review of the Effect of Cystic Fibrosis Treatments on the Nasal Potential Difference Test in Animals and Humans. Diagnostics, 13(19), 3098. https://doi.org/10.3390/diagnostics13193098

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop